New clinical panerty test

Details of a new UK clinical trial to determine the risks and benefits of gender-quenching drugs in children and young people whose gender has been revealed.

It follows the ban on drugs for gender treatment last year After a major review raised concerns about the lack of clinical evidence of their safety for under-18s.

Researchers from King’s College London said the trial will include about 220 children under the age of 16 who have experienced the impact of drugs on their physical, social and emotional well-being.

Some clinicians and campaigners question whether the test is ethical.

Prof Emily Simonff, Leader of the Study and Professor of Child and Adolescent Psychiatry at College London (KCL), but this research focuses on the physical and mental health of how to support the physical and heal the health of how to heal the health of dealing with young people and thinking of young people with sexual stability. “

Puberty Blockersalso known as pamperty suppressing hormones (PSH), drugs used to delay or prevent childhood from occurring.

They are used to treat some young people who have gender stability – when a person’s gender does not correspond to the sex registered at birth – or there is a reason for difficulty.

As a result of the uncertainty of the safety of medicines, highlighted by the cass review Towards gender care, led by Pediatrician Dr Hilary Cass, doctors will now only offer treatment to under-18s as part of a research study.

Last year, the government brought a UK-wide Non-Fire Restrictions Medicines prescribed privately or on the NHS to children and young people whose gender identity is in question.

The new clinical trial, called access, will involve children who are currently accessing gender services and have a diagnosis of gender incongrufence.

All of them have reached childhood, but are younger than 16 – and must meet strict criteria, undergo intensive medical and psychological screening before they are allowed to start taking puberty blockers.

A team of specialist NHS Doctors must have a full picture of the young person’s wellbeing before deciding whether they think they deserve treatment.

The young person must demonstrate that they have a good understanding of the potential impact of taking job blockers to give their consent, and their parent or legal guardian must agree. They will be provided with ongoing psychological support.

In order to explore the effect of the drugs, the researchers plan to start one treatment group directly into the treatment and another group later. Children in these groups will be selected at random.

KCL researchers say there is no minimum age for taking the drugs, but the behavior usually begins at age 11 for girls.

The test will look at issues such as bone density, brain development and mental health and will improve over time.

The research team said that the court has granted ethical approval and is expected to start in January, with five to six children recruited each month. The first results should be available in about four years.

Along with this, a larger observational study involving 3,000 children will investigate different types of support and how effective they are.

Attempts to boost employment have proved controversial, with campaigners threatening legal action.

Keira Bell, who took the Tavistock Gender Clinic to Court in 2020 after she was given puberty blockers and cross-sex hormones as a teenager, said the trial should be stopped immediately. If it doesn’t, he said he and another campaign will begin a judicial review of the high court’s review procedures.

He said it was “disgusting” that children were exposed to drugs when they were banned because they were “unsafe”.

In his case, The High Court ruled that those under 16 “are unlikely to give informed consent” of puberty blockers, but it was later overturned by an appeals court ruling that Doctors can decide whether young people can give consent to treatment.

Some clinics from the clinical advisory network of sex and gender, which campaigns for solid science and improved treatment options for people in the treatment of people who question the treatment, which also asked if the test can be carried out.

A spokesperson for the charity stonewall, which campaigns for the rights of LGBTSQ+ people, said that all young people should have access to the best medical care, guided by evidence.

“We urge the government and policy to invest in the delivery of good health care for young people and make sure that the voices of young people and their families are at the core.”